MARKET

BIAFW

BIAFW

bioAffinity Tech
NASDAQ
0.1402
-0.0164
-10.47%
Closed 11:43 06/17 EDT
OPEN
0.1402
PREV CLOSE
0.1566
HIGH
0.1402
LOW
0.1402
VOLUME
997
TURNOVER
0
52 WEEK HIGH
0.8121
52 WEEK LOW
0.0525
MARKET CAP
--
P/E (TTM)
-0.0124
1D
5D
1M
3M
1Y
5Y
1D
bioAffinity Technologies prices USD 3.2 million public offering at USD 0.8 per share
PUBT · 21h ago
BIOAFFINITY TECHNOLOGIES ANNOUNCES PRICING OF $3.2 MILLION OFFERING
Reuters · 21h ago
bioAffinity Technologies to host veteran lung health screening webinar with Philips, 4DMedical
PUBT · 1d ago
bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans
Barchart · 2d ago
Weekly Report: what happened at BIAFW last week (0608-0612)?
Weekly Report · 3d ago
BIOAFFINITY TECHNOLOGIES - ASSUMED PUBLIC OFFERING PRICE SET AT $1.52 PER SHARE - SEC FILING
Reuters · 5d ago
BIOAFFINITY TECHNOLOGIES - OFFERS 2.63 MLN SHARES OF COMMON STOCK - SEC FILING
Reuters · 5d ago
Weekly Report: what happened at BIAFW last week (0601-0605)?
Weekly Report · 06/08 10:07
More
About BIAFW
bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatment. Its segments include Diagnostic Research and Development (R&D) and Laboratory Services. Its Diagnostic R&D segment includes research and development and clinical development on diagnostic tests. Its Laboratory services include all the operations of Village Oaks and PPLS, in addition to sales and marketing of CyPath Lung from bioAffinity. Its first product, CyPath Lung, addresses the need for noninvasive detection of early-stage lung cancer. The CyPath Lung test enables physicians to more confidently identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening.

Webull offers bioAffinity Technologies Inc stock information, including NASDAQ: BIAFW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIAFW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIAFW stock methods without spending real money on the virtual paper trading platform.